Opportunistic infections of the CNS in patients with AIDS: Diagnosis and management

CNS Drugs

Volumn 17, Issue 12, 2003, Pages 869-887

  Collazos, Julio ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMANTADINE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CIDOFOVIR; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYTARABINE; DAPSONE; DOXYCYCLINE; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G ANTIBODY; ITRACONAZOLE; PYRIMETHAMINE; SULFADIAZINE; TRIMETREXATE; VALGANCICLOVIR; VIDARABINE; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ANTIBODY TITER; BLOOD TOXICITY; BRAIN BIOPSY; BRAIN REGION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ENCEPHALITIS; FEVER; FUNGAL MENINGITIS; GEOGRAPHIC DISTRIBUTION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; JC VIRUS; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; QUANTITATIVE ANALYSIS; REVIEW; SERODIAGNOSIS; SIDE EFFECT; SKIN DEFECT; SURVIVAL RATE; SYMPTOM; TOXOPLASMA GONDII; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CENTRAL NERVOUS SYSTEM INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; ENCEPHALITIS; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MENINGITIS, CRYPTOCOCCAL; TOXOPLASMOSIS;

EID: 0141863360     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317120-00002     Document Type: Review

References (147)

1. Fischer PA, Enzensberger W. Neurological complications in AIDS. J Neurol 1987 Jun; 234 (5): 269-79
2. Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002 Jan; 34: 103-15
3. Berger JR, Levy RM. The neurologic complications of human immunodeficiency virus infection. Med Clin North Am 1993 Jan; 77 (1): 1-23
4. McArthur JC. Neurologic manifestations of AIDS. Medicine 1987; 66 (6): 407-37
5. Gray F, Gherardi R, Scaravilli F. The neuropathology of the acquired immune deficiency syndrome (AIDS): a review. Brain 1988 Apr; 111 (Pt 2): 245-66
6. Masliah E, DeTeresa RM, Mallory ME, et al. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000 Jan 7; 14 (1): 69-74
7. Conti S, Masocco M, Pezzotti P, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immun Defic Syndr Hum Retrovirol 2000 Dec 15; 25 (5): 451-8
8. Guzmán MT, Gaspar G, Castilla V, et al. Survival after first episodes of HIV: opportunistic diseases and its changes over the decade 1990-2000 in the COMESEM cohort study [abstract TuPeC4732]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, 452
9. Ammassari A, Cinque P, Lorenzini P, et al. HAART exposure influences distribution and characteristics of HlV-associated neurologic disorders: data from Italian Registry Investigation Neuro AIDS (IRINA) [abstract ThPeB7370]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, 426
10. Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002 Jun; 8 (3): 158-67
11. Renold C, Sugar A, Crave JP. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine 1992; 71 (4): 224-39
12. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994 Nov 15; 121 (10): 769-85
13. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992 Aug; 15: 211-22
14. Maschke M, Kastrup O, Esser S, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000 Sep; 69 (3): 376-80
15. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001 Jan 23; 56 (2): 257-60
16. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001 Nov 15; 33: 1747-55
17. Raffi F, Aboulker JP, Michelet C, et al. A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. AIDS 1997; 11 (2): 177-84
18. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992 Dec 3; 327 (23): 1643-8
19. Katlama C, De Wit S. O'Doherty E, et al. Pyrimethamineclindamycin vs pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996 Feb; 22: 268-75
20. Bartlett JG, Gallant JE. Medical management of HIV infection. 2001-2002 ed. Baltimore (MD): Johns Hopkins University, 2001
21. Skiest DJ, Erdman W, Chang WE, et al. SPECT thallium-201 combined with toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000 May; 40 (3): 274-81
22. Derouin F, Leport C, Pueyo S, et al. Predictive value of toxoplasma antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. AIDS 1996; 10 (13): 1521-7
23. Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infecred patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11 (1): 1-17
24. Potasman I, Resnick L, Luft BJ, et al. Intrathecal production of antibodies against Toxoplasma gondii in patients with fox-oplasmic encephalitis and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988 Jan; 108 (1): 49-51
25. Julander I, Martin C, Lappalainen M, et al. Polymerase chain reaction for diagnosis of cerebral toxoplasmosis in cerebrospinal fluid in HIV-positive patients. Scand J Infect Dis 2001; 33 (7): 538-41
26. Novati R, Castagna A, Morsica G, et al. Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. AIDS 1994 Dec; 8 (12): 1691-4
27. Ciricillo SJ, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990 Nov; 73 (5): 720-4
28. Pierce MA, Johnson MD, Maciunas RJ, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995 Oct 15; 123 (8): 594-8
29. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992 Jan 1; 116 (1): 33-43
30. Behbahani R, Moshfeghi M, Baxter JD. Therapeutic approaches for AIDS-related toxoplasmosis. Ann Pharmacother 1995 Jul-Aug; 29: 760-8
31. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 1998 Jun; 42 (6): 1346-9
32. Lundgren J, Masur H. New approaches to managing opportunistic infections. AIDS 1999; 13 Suppl, A: S227-34
33. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2002 Jun 14; 51 (RR-8): 1-52
34. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000 May 11; 342 (19): 1416-29
35. Miro JM, Lejeune M, Claramonte X, et al. Toxoplasma gondii-specific T-cell responses are restored in AIDS patients who discontinued toxoplasma encephalitis (TE) secondary prophylaxis (SP) after immunological reconstitution due to potent antiretroviral therapy (HAART) [abstract 632-W]. 9th Conference on Retrovirus and Opportunistic Infections; 2002 Feb 24-28; Seattle. Alexandria (VA): Foundation for Retrovirelogy and Human Health, 2002: 285
36. Holman RC, Janssen RS, Buehler JW, et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991 Nov; 41 (11): 1733-6
37. McGuire D, Barhite S, Hollander H, et al. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy. Ann Neurol 1995 Mar; 37 (3): 395-9
38. Berger JR, Kaszovitz B, Post JD, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: a review of the literature with a report of sixteen cases. Ann Intern Med 1987 Jul; 107 (1): 78-87
39. Dworkin MS, Wan PC, Hanson DL, et al. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency vires-infected patients in the protease inhibitor era. J Infect Dis 1999 Sep; 180 (3): 621-5
40. Albrecht H, Hoffman C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12 (10): 1149-54
41. Fong IW, Toma E. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Clin Infect Dis 1995 May; 20: 1305-10
42. Whiteman MLH, Post MID, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993 Apr; 187 (1): 233-40
43. Tassie JM, Gasnault J, Bentata M, et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. AIDS 1999 Oct 1; 13 (14): 1881-7
44. De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000 Oct; 182: 1077-83
45. Antinori A, Ammassari A, Giancola ML, et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001 Aug; 7 (4): 323-8
46. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001 Apr; 75 (7): 3483-7
47. Power C, Kong PA, Crawford TO, et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993 Sep; 34 (3): 339-50
48. Hofman FM, Dohadwala MM, Wright AD, et al. Exogenous tat protein activates central nervous system-derived endothelial cells. J Neuroimmunol 1994 Oct; 54 (1-2): 19-28
49. Valle LD, Croul S, Morgello S, et al. Detection of HIV-1 Tat and JCV capsid protein, VPI, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 2000 Jun; 6 (3): 221-8
50. Chowdhury M, Kundu M, Khalili K. GA/GC-rich sequence confers Tat responsiveness to human neurotropic virus promoter, JCVL, in cells derived from central nervous system. Oncogene 1993 Apr; 8 (4): 887-92
51. De Luca A, Giancola ML, Ammassari A, et al. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 2000 Sep 29; 14 (14): F117-21
52. Giudici B, Vaz B, Bossolasco S. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000 Jan; 30: 95-9
53. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999 Aug; 5 (4): 421-9
54. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of AIDS-associated progressive multifocal leukoencephalopathy (PML) in patients treated with HAART (GESIDA 11/99) [abstract 10]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8: Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 2001: 45
55. Quinlivan EB, Norris M, Bouldin TW, et al. Subclinical central nervous system infection with JC virus in patients with AIDS. J Infect Dis 1992 Jul; 166: 80-5
56. Vazeux R, Cumont M, Girard PM, et al. Severe encephalitis resulting from coinfections with HIV and JC virus. Neurology 1990 Jun; 40: 944-8
57. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997 Jul; 176 (1): 250-4
58. Garcia de Viedma D, Alonso R, Miralles P, et al. Dual qualitative-quantitative nested PCR for detection of JC virus in cerebrospinal fluid: high potential for evaluation and monitoring of progressive multifocal leukoencephalopathy in AIDS patients receiving highly active antiretroviral therapy. J Clin Microbiol 1999 Mar; 37 (3): 724-8
59. Andréoletti L, Dubois V, Lescieux A, et al. Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy. AIDS 1999; 13 (12): 1469-75
60. Yiannoutsos CT, Major EO, Curfman B, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999 Jun; 45 (6): 816-21
61. De Luca A, Giancola ML, Cingolani A, et al. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 1999 Mar; 28 (3): 624-8
62. Taoufik Y, Gasnault J, Karaterki A, et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 1998 Dec; 178 (6): 1816-20
63. García de Viedma D, Díaz Infantes M, Miralles P, et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis 2002 Jun 15; 34: 1568-75
64. Collazos J, Mayo J, Martinez E, et al. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999 Jul 30; 13 (11): 1426-8
65. Miralles P, Berenguer J, Lacruz C, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001 Sep 28; 15 (14): 1900-2
66. Quinlivan EB, Norris M, Bouldin TW, et al. Subclinical central nervous system infection with JC virus in patients with AIDS. J Infect Dis 1992 Jul; 166 (1): 80-5
67. Kotecha N, George MJ, Smith TW, et al. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998 Dec; 105 (6): 541-3
68. Woo HH, Rezai AR, Knopp EA, et al. Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations: case report. Neurosurgery 1996 Nov; 39 (5): 1031-5
69. Berger JR, Mucke L. Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1988 Jul; 38: 1060-5
70. Lortholary O. Pialoux G, Dupont B, et al. Prolonged survival of a patient with AIDS and progressive multifocal leukoencephalopathy. Clin Infect Dis 1994 May; 18: 826-7
71. Geschwind MD, Skolasky RI, Royal WS, et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001 Aug; 7 (4): 353-7
72. Antinori A, De Luca A, Ammassari A, et al. Failure of cytarabine and increased JC virus-DNA burden in the cerebrospinal fluid of patients with AIDS-related progressive multifocal leucoencephalopathy. AIDS 1994; 8 (7): 1022-4
73. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998 May 7; 338 (19): 1345-51
74. Andrei G, Snoeck R, Vandeputte M, et al. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997 Mar; 41 (3): 587-93
75. De Luca A, Giancola ML, Ammassari A, et al. Clinical and virological correlates of longer survival in AIDS-associated progressive multifocal leukoencephalopathy [abstract 299]. 7th Conference on Retrovirus and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 133
76. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16 (13): 1791-7
77. Sadler M, Chinn R, Healy J. New treatments for progressive multifocal leukoencephalopathy in HIV-1 infected patients. AIDS 1998; 12 (5): 533-5
78. Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001 Aug; 7 (4): 375-81
79. Segarra-Newnham M, Vodolo KM. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother 2001 Jun; 35 (6): 741-4
80. Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 1999 Jan 14; 13 (1): 1-22
81. Mayo J, Collazos J, Martínez E. Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy. AIDS 1998; 12 (13): 1720-2
82. Tantisiriwat W, Tebas P, Clifford DB, et al. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999 May; 28: 1152-4
83. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999 Feb; 52 (3): 623-5
84. Miralles P, Berenguer J, García de Viedma D, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998; 12 (18): 2467-72
85. Gasnault J, Kahraman M, de Goere MG, et al. Analysis of anti-JC virus CD4 T-cell response in healthy subjects and in HIV+ patients with or without progressive multifocal leukoencephalopathy [abstract 727-W]. 9th Conference on Retrovirus and Opportunistic Infections; 2002 Feb 24-28; Seattle. Alexandria (VA): Foundation for Retrovirology and Human Health, 2002: 317
86. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995 Aug; 21 Suppl. 1: S103-7
87. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002 May 3; 16 (7): 1031-8
88. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 May; 22 Suppl. 2: S119-23
89. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002 Apr 15; 34 (8): 1098-107
90. van Elden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000 Dec 1; 14 (17): 2787-8
91. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000 Jan; 30: 47-54
92. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988 Apr; 157 (4): 624-8
93. Powderly WG. Cryptococcal meningitis in AIDS. Clin Infect Dis 1993 Nov; 17: 837-42
94. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997 Jul 3; 337 (1): 15-21
95. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992 Jan 9; 326 (2): 83-9
96. Robinson PA, Bauer M, Leal MAE, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999 Jan; 28: 82-92
97. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999 Feb; 28 (2): 291-6
98. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000 Apr; 30 (4): 710-8
99. Feldmesser M, Harris C, Reichberg S, et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996 Oct; 23 (4): 827-30
100. Manfredi R, Moroni A, Mazzoni A, et al. Isolate detection of cryptococcal polysaccharide antigen in cerebrospinal fluid samples from patients with AIDS. Clin Infect Dis 1996 Oct; 23: 849-50
101. Leenders ACAP, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11 (12): 1463-71
102. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992 Mar 19; 326 (12): 793-8
103. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 Feb; 22 (2): 315-21
104. Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996 May; 22: 838-40
105. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994 Oct; 19: 741-5
106. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998 Jun; 26 (6): 1362-6
107. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990 Aug 1; 113 (3): 183-7
108. Monari C, Casadevall A, Baldelli F, et al. Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy. AIDS 2000 Dec 1; 14 (17): 2699-708
109. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002 Aug 20; 137 (4): 239-50
110. Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994 May; 18 (5): 789-92
111. Larsen RA. Editorial response: a comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999 Feb; 28 (2): 297-8
112. Price DA, Klein JL, Fisher M, et al. Potential role of granulocyte-macrophage colony-stimulating factor in the treatment of HIV-associated cryptococcal meningitis. AIDS 1997; 11 (5): 693-4
113. Denning DW, Armstrong RW, Lewis BH, et al. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991 Sep; 91: 267-72
114. Rex JR, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72 (4): 207-24
115. Torres OH, Negredo E, Ris J, et al. Visual loss due to Cryptococcus neoformans meningitis in AIDS patients. AIDS 1999; 13 (4): 530-2
116. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 1995 Apr; 20: 747-54
117. Mocroft A, Katlama C, Johnson AM. et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000 Jul 22; 356 (9226): 291-6
118. Cinque P, Lazzarin A. Management strategies for herpesvirus infections of the CNS: immunocompetent and immunocompromised patients. CNS Drugs 2000 Aug; 14 (2): 95-113
119. Selik RM, Byers Jr RH, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immun Defic Syndr 2002 Apr 1; 29 (4): 378-87
120. Anders HJ, Goebel FD. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS 1999 Mar; 10 (3): 151-9
121. Kalayjian RC, Cohen ML, Bonomo RA, et al. Cytomegalovirus ventriculoencephalitis in AIDS: a syndrome with distinct clinical and pathologic features. Medicine (Baltimore) 1993 Mar; 72 (2): 67-77
122. Arribas JR, Storch GA, Clifford DB, et al. Cytomegalovirus encephalitis. Ann Intern Med 1996 Oct 1; 125 (7): 577-87
123. Cohen BA. Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. Neurology 1996 Feb; 46: 444-50
124. Holland NR, Power C, Mathews VP, et al. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology 1994 Mar; 44: 507-14
125. Grassi MP, Clerici F, Perin C, et al. Microglial nodular encephalitis and ventriculoencephalitis due to cytomegalovirus infection in patients with AIDS: two distinct clinical patterns. Clin Infect Dis 1998 Sep; 27: 504-8
126. Maschke M, Kastrup O, Diener HC. CNS manifestations of cytomegalovirus infections: diagnosis and treatment. CNS Drugs 2002; 16 (5): 303-15
127. Vinters HV, Kwok MK, Ho HW, et al. Cytomegalovirus in the nervous system of patients with the acquired immune deficiency syndrome. Brain 1989 Feb; 112 (Pt 1): 245-68
128. Berman SM, Kim RC. The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. Am J Med 1994 May; 96: 415-9
129. Laskin OL, Stahl-Bayliss CM, Morgello S. Concomitant herpes simplex virus type 1 and cytomegalovirus ventriculoencephalitis in acquired immunodeficiency syndrome. Arch Neurol 1987 Aug; 44: 843-7
130. Moulignier A, Mikol J, Gonzalez-Canali G, et al. AIDS-associated cytomegalovirus infection mimicking central nervous system tumors: a diagnostic challenge. Clin Infect Dis 1996 Apr; 22: 626-31
131. Anders HJ, Goebel FD. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis 1998 Aug; 27 (2): 345-52
132. Cohen BA, McArthur JC, Grohman S, et al. Neurologic prognosis of cytomegalovirus polyradiculomyelopathy in AIDS. Neurology 1993 Mar; 43 (3 Pt 1): 493-9
133. Anduze-Faris BM, Fillet AM, Gozlan J, et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 2000 Mar 31; 14 (5): 517-24
134. Mathiesen T, Sonnerborg A, von Sydow M, et al. IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients. J Med Virol 1988 May; 25 (1): 17-26
135. Weber T, Beck R, Stark E, et al. Comparative analysis of intrathecal antibody synthesis and DNA amplification for the diagnosis of cytomegalovirus infection of the central nervous system in AIDS patients. J Neurol 1994 Jun; 241 (7): 407-14
136. Cinque P, Baldanti F, Vago L, et al. Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. J Infect Dis 1995 Jun; 171 (6): 1603-6
137. Revello MG, Percivalle E, Sarasini A, et al. Diagnosis of human cytomegalovirus infection of the nervous system by pp65 detection in polymorphonuclear leukocytes of cerebrospinal fluid from AIDS patients. J Infect Dis 1994 Nov; 170 (5): 1275-9
138. Zhang F, Tetali S, Wang XP, et al. Detection of human cytomegalovirus pp67 late gene transcripts in cerebrospinal fluid of human immunodeficiency virus type 1-infected patients by nucleic acid sequence-based amplification. J Clin Microbiol 2000 May; 38 (5): 1920-5
139. Cinque P, Cleator GM, Weber T, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol 1998 Feb; 4 (1): 120-32
140. Arribas JR, Clifford DB, Fichtenbaum CJ, et al. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995 Aug; 172 (2): 527-31
141. Bernasconi S, Cinque P, Peri G, et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis 1996 Nov; 174 (5): 1098-101
142. Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002 Jun; 36 (6): 1075-9
143. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002 Apr 11; 346 (15): 1119-26
144. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med 1998 May 11; 158: 957-69
145. Sadler M, Morris-Jones S, Nelson M, et al. Successful treatment of cytomegalovirus encephalitis in an AIDS patient using cidofovir. AIDS 1997 Aug; 11 (10): 1293-4
146. Blick G, Garton T, Hopkins U, et al. Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997 May 1; 15 (1): 84-5
147. Tsertsvadze T, Gochitashvili N, Sharvadze L. Cytomegalovirus infection in HIV patients [abstract ThPeB7304]. XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, 411